J+D FORECASTING LAUNCHES INNOVATIVE ONCOLOGY FORECASTING SOFTWARE
Onco+ is an Excel add-in specifically designed for oncology forecasting
J+D Forecasting, one of the world’s leading pharmaceutical forecasting companies, has today announced the launch of Onco+, as the latest addition to its comprehensive suite of forecasting software.
The unique Onco+ software has been specifically created for anyone involved in oncology forecasting to help them to produce transparent patient flow models. Onco+ incorporates changes in treatment paradigms as well as the progression of patients. Ultimately, Onco+ offers a more accurate approach to oncology forecasting for any cancer type and mutation.
Built upon forecasting best practise principles, Onco+ is a Microsoft Excel add-in, that guides the user through a step by step process incorporating stages of cancer, lines of therapy, regimens, and therapy restrictions. Onco+ has all oncological variables incorporated and therefore reduces the need for costly third-party involvement.
Onco+ uses patient flow modelling to enable analysts to track the flow of patients for any type of cancer at a granular level with the opportunity to include mutations, re-treatment rates, and relapse rates. It’s this, combined with advanced functionality to look at the risk probability, and the agility to make instant changes, that makes Onco+ the ideal solution for anyone involved in new product planning in oncology.
David James, CEO at J+D Forecasting, said:
“The oncology sector is constantly evolving and the ability to produce forecasts quickly, by utilising the most accurate and user-friendly approach, has never been more important. In the pharma sector, an ineffective forecasting approach can lead to poor decision making and have catastrophic consequences on the business.
“Onco+ is the most innovative software solution on the market that can make an astonishing difference to the credibility and confidence in a product forecast. Over the years we’ve developed forecasts for some of the biggest names in the oncology industry, and have used this vast experience and knowledge to develop an innovative solution that is not only the market leader, but can also save the industry a lot of time and expense.”